Mabwell Achieves Milestone with NMPA’s Acceptance of IND Application for 6MW5311 Bispecific Antibody
On April 15, 2026, Mabwell (688062.SH), a leading biopharmaceutical company based in Shanghai, announced a significant advancement in its drug development pipeline. The National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for Mabwell's innovative LILRB4/CD3 T Cell Engager (TCE) bispecific antibody known as RD code 6MW5311. This groundbreaking drug candidate is specifically being developed for various hematologic malignancies, including Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), and Multiple Myeloma (MM).
The significance of 6MW5311 cannot be overstated, as it represents the first bispecific antibody of its kind to have a clinical trial application submitted globally. The innovative structure of this antibody not only holds promise for clinical development but also a considerable market potential. Currently, the U.S. IND application is in pre-IND stages with a formal submission to the FDA expected in the second quarter of 2026.
Developed utilizing the advanced T Cell Engager technology, 6MW5311 features a unique ``2+1`` asymmetric molecular structure. This allows it to simultaneously target LILRB4 and CD3 proteins, thereby establishing an immunological synapse that links tumor cells directly with T cells. As a result, T cells are activated effectively to kill tumors.
A key aspect of this molecule's efficacy lies in its exceptional design, which employs steric hindrance. This innovative feature minimizes the binding activity of the CD3 antibody to T cells in the absence of tumor cells. Thus, T cells get specifically activated only in the presence of tumor cells, significantly enhancing safety and anti-tumor efficacy.
Initial in vitro studies have showcased that 6MW5311 exhibits strong cytotoxic effects across numerous tumor cell lines and patient-derived samples, particularly highlighting its ability to significantly inhibit tumor growth in preclinical models. Furthermore, its safety profile was solidified through evaluations in cynomolgus monkeys, demonstrating favorable outcomes.
The T Cell Engager technology has revolutionized treatment protocols for various lymphoma types, contributing to numerous successful treatment launches. However, the challenges of treating AML and CMML remain, as existing regimens are primarily limited to chemotherapy, hematopoietic stem cell transplants, and targeted therapies tailored for specific mutations, with no TCE products yet authorized for these conditions.
As for Acute Myeloid Leukemia (AML), it represents a diverse and malignant disorder linked to myeloid stem cells, with a high mortality rate. In 2022 alone, around 172,000 new cases were diagnosed worldwide, a number that is projected to rise significantly in the coming years. In contrast, Chronic Myelomonocytic Leukemia (CMML) represents a rare class of hematologic malignancy, sharing features with both myelodysplastic syndromes and myeloproliferative neoplasms, currently lacking effective treatment strategies.
Multiple Myeloma (MM), another focus of 6MW5311, is characterized by the uncontrolled rise of abnormal plasma cells in the bone marrow. Though therapy advancements, including proteasome inhibitors and monoclonal antibodies have positively impacted survival rates, MM remains largely incurable, with many patients facing multiple relapses during their treatment journey.
Mabwell’s commitment to innovative research and patient-centered solutions aims to address these daunting challenges in oncology, emphasizing their mission: "Explore Life, Benefit Health," and their vision of turning novel ideas into tangible healthcare solutions. This IND acceptance symbolizes a substantial step forward, not just for Mabwell, but for patients suffering from these challenging conditions, who await better treatment options in the near future. For more detailed information about Mabwell and their products, please visit their official website.
The significance of 6MW5311 cannot be overstated, as it represents the first bispecific antibody of its kind to have a clinical trial application submitted globally. The innovative structure of this antibody not only holds promise for clinical development but also a considerable market potential. Currently, the U.S. IND application is in pre-IND stages with a formal submission to the FDA expected in the second quarter of 2026.
Developed utilizing the advanced T Cell Engager technology, 6MW5311 features a unique ``2+1`` asymmetric molecular structure. This allows it to simultaneously target LILRB4 and CD3 proteins, thereby establishing an immunological synapse that links tumor cells directly with T cells. As a result, T cells are activated effectively to kill tumors.
A key aspect of this molecule's efficacy lies in its exceptional design, which employs steric hindrance. This innovative feature minimizes the binding activity of the CD3 antibody to T cells in the absence of tumor cells. Thus, T cells get specifically activated only in the presence of tumor cells, significantly enhancing safety and anti-tumor efficacy.
Initial in vitro studies have showcased that 6MW5311 exhibits strong cytotoxic effects across numerous tumor cell lines and patient-derived samples, particularly highlighting its ability to significantly inhibit tumor growth in preclinical models. Furthermore, its safety profile was solidified through evaluations in cynomolgus monkeys, demonstrating favorable outcomes.
The T Cell Engager technology has revolutionized treatment protocols for various lymphoma types, contributing to numerous successful treatment launches. However, the challenges of treating AML and CMML remain, as existing regimens are primarily limited to chemotherapy, hematopoietic stem cell transplants, and targeted therapies tailored for specific mutations, with no TCE products yet authorized for these conditions.
As for Acute Myeloid Leukemia (AML), it represents a diverse and malignant disorder linked to myeloid stem cells, with a high mortality rate. In 2022 alone, around 172,000 new cases were diagnosed worldwide, a number that is projected to rise significantly in the coming years. In contrast, Chronic Myelomonocytic Leukemia (CMML) represents a rare class of hematologic malignancy, sharing features with both myelodysplastic syndromes and myeloproliferative neoplasms, currently lacking effective treatment strategies.
Multiple Myeloma (MM), another focus of 6MW5311, is characterized by the uncontrolled rise of abnormal plasma cells in the bone marrow. Though therapy advancements, including proteasome inhibitors and monoclonal antibodies have positively impacted survival rates, MM remains largely incurable, with many patients facing multiple relapses during their treatment journey.
Mabwell’s commitment to innovative research and patient-centered solutions aims to address these daunting challenges in oncology, emphasizing their mission: "Explore Life, Benefit Health," and their vision of turning novel ideas into tangible healthcare solutions. This IND acceptance symbolizes a substantial step forward, not just for Mabwell, but for patients suffering from these challenging conditions, who await better treatment options in the near future. For more detailed information about Mabwell and their products, please visit their official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.